ONC - BeOne Medicines Ltd

297.04
-17.320   -5.831%

Share volume: 503,414
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$314.36
-17.32
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
51%
Profitability 45%
Dept financing 28%
Liquidity 75%
Performance 58%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.29%
1 Month
-15.61%
3 Months
-10.37%
6 Months
-6.81%
1 Year
15.44%
2 Year
14.69%
Key data
Stock price
$297.04
P/E Ratio 
117.17
DAY RANGE
$293.27 - $301.94
EPS 
$0.20
52 WEEK RANGE
$196.45 - $385.22
52 WEEK CHANGE
$13.28
MARKET CAP 
33.619 B
YIELD 
N/A
SHARES OUTSTANDING 
222.510 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$410,639
AVERAGE 30 VOLUME 
$282,735
Company detail
CEO: John V. Oyler
Region: US
Website: beigene.com
Employees: 9,000
IPO year: 2016
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)

Recent news